JEMPERLI (dostarlimag-gxly)
TherapyGSK
JEMPERLI (dostarlimab-gxly) from GSK is a PD-1–directed immunotherapy used in mismatch-repair–deficient tumors.
Approvals
3
Indications
2
Biomarkers
2
Mapped tests
2
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and JEMPERLI. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where JEMPERLI is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Endometrial Carcinoma (EC) Solid Tumor · Endometrium | deficient mismatch repair (dMMR) proteins
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for JEMPERLI.
| Level | Biomarker criteria | Notes | |
|---|---|---|---|
| Solid Tumors | MSI-High
| ||
| Solid Tumors | deficient mismatch repair (dMMR) proteins
|
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering JEMPERLI for eligible patients.
Test
MI Cancer Seek (MCS)
Caris Life Sciences
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →
Test
Ventana MMR RxDx Panel
Ventana Medical Systems, Inc. (Roche Diagnostics)
Method
IHC
Specimen
Tissue (FFPE)
2 approvalsView test profile →